Pfizer Inc is not in discussions with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use in China, according to the company’s chief executive, Albert Bourla, on Monday, January 9. However, the company is in discussions about the price of the branded product, he said. Reuters reported on Friday that China was in negotiations with …
